Adial Pharmaceuticals Equity 2024

Adial Pharmaceuticals Aktienanalyse

What does Adial Pharmaceuticals do?

Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Adial Pharmaceuticals's Equity

Adial Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Adial Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Adial Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Adial Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Adial Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Adial Pharmaceuticals Stock

What is the equity of Adial Pharmaceuticals this year?

Adial Pharmaceuticals has equity of 4.08 M USD this year.

What was the equity of Adial Pharmaceuticals compared to the previous year?

The equity of Adial Pharmaceuticals has increased/decreased by 24.5% increased compared to the previous year.

What impact does a high equity have on investors of Adial Pharmaceuticals?

A high equity is advantageous for investors of Adial Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Adial Pharmaceuticals?

A low equity can be a risk for investors of Adial Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Adial Pharmaceuticals affect the company?

An increase in equity of Adial Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Adial Pharmaceuticals affect the company?

A reduction in equity of Adial Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Adial Pharmaceuticals?

Some factors that can affect the equity of Adial Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Adial Pharmaceuticals so important for investors?

The equity of Adial Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Adial Pharmaceuticals take to change the equity?

To change equity, Adial Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Adial Pharmaceuticals pay?

Over the past 12 months, Adial Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adial Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adial Pharmaceuticals?

The current dividend yield of Adial Pharmaceuticals is .

When does Adial Pharmaceuticals pay dividends?

Adial Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adial Pharmaceuticals?

Adial Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adial Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adial Pharmaceuticals located?

Adial Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adial Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adial Pharmaceuticals from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Adial Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Adial Pharmaceuticals in the year 2023?

In the year 2023, Adial Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adial Pharmaceuticals pay out the dividend?

The dividends of Adial Pharmaceuticals are distributed in USD.